Program
Poliovirus Vaccine, Inactivated
Also written as “sIPV”, “IPV” and “Poliorix™”.
Its studies are mostly in Poliomyelitis · Gastroenteritis · Streptococcal Infections · Tetanus, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 50 open or running | phase 3since Oct 19, 2007 | Oct 19, 2007 | none ahead |
| Sinovac Biotech | 41 open or running | phase 4since Jan 29, 2024 | May 4, 2018 | none ahead |
| Beijing Minhai Biotechnology | 20 open or running | phase 3since Dec 12, 2024 | Dec 12, 2024 | none ahead |
| Johnson & Johnson | 20 open or running | phase 2since Jun 12, 2018 | Jan 24, 2017 | none ahead |
| E-MO Biology | 10 open or running | phase 4since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| Sinopharm | 10 open or running | phase 4since Aug 8, 2019 | Aug 8, 2019 | none ahead |
| Takeda | 10 open or running | phase 2since Mar 24, 2017 | Mar 24, 2017 | none ahead |
Also a collaborator on its studies: Beijing Institute of Biological Products.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Oct 19, 2007.
- Nov 25, 2009Phase 3 study in PoliomyelitisGlaxoSmithKline · NCT01021293 · 1,101 enrolled · China
- Oct 6, 2011Phase 3 study in TetanusGlaxoSmithKline · NCT01449812 · 831 enrolled · China
- Jan 24, 2017Johnson & Johnson’s first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT03032588 · 32 enrolled · Belgium
- Mar 24, 2017Takeda’s first study: phase 2 study in PoliomyelitisNew to TakedaTakeda · NCT03092791 · 340 enrolled · Panama
- May 4, 2018Sinovac Biotech’s first study: phase 3 study in PoliomyelitisNew to Sinovac BiotechSinovac Biotech · NCT03526978 · 1,200 enrolled · China
- Jun 12, 2018Phase 2 study in HealthyJohnson & Johnson · NCT03566940 · 302 enrolled · Philippines
- Aug 8, 2019Sinopharm’s first study: phase 4 study in VaccinationNew to SinopharmSinopharm · NCT04051736 · 360 enrolled · China
- Nov 16, 2020E-MO Biology’s first study: phase 4 study in SARS-CoV-2New to E-MO BiologyE-MO Biology · NCT04639375 · 300 enrolled · United States
- Jan 29, 2024Phase 4 study in PoliomyelitisSinovac Biotech · NCT06346834 · 200 enrolled · China
- Mar 19, 2024Phase 3 study in GastroenteritisGlaxoSmithKline · NCT06331156 · 400 enrolled · China
- May 29, 2024Phase 4 study in PoliomyelitisSinovac Biotech · NCT06442449 · 889 enrolled · China
- Dec 12, 2024Beijing Minhai Biotechnology’s first study: phase 3 study in PoliomyelitisNew to Beijing Minhai BiotechnologyBeijing Minhai Biotechnology · NCT06752174 · 300 enrolled · China
- Apr 22, 2025Phase 4 study in PoliomyelitisSinovac Biotech · NCT07354269 · 180 planned · China
- Dec 9, 2025Phase 3 study in PoliomyelitisBeijing Minhai Biotechnology · NCT07297186 · 1,200 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis”NCIt, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07297186Poliomyelitis · China | 3 | Completed | Beijing Minhai Biotechnology | Apr 10, 2023 | 1,200 |
| NCT07354269Poliomyelitis · China | 4 | Recruiting | Sinovac Biotech | Apr 11, 2026 | 180 |
| NCT06752174Poliomyelitis · China | 3 | Completed | Beijing Minhai Biotechnology | Apr 12, 2024 | 300 |
| NCT06442449Poliomyelitis · China | 4 | Completed | Sinovac Biotech | Sep 10, 2025 | 889 |
| NCT06331156Gastroenteritis · China | 3 | Completed | GlaxoSmithKline | Oct 22, 2024 | 400 |
| NCT06346834Poliomyelitis · China | 4 | Completed | Sinovac Biotech | Sep 6, 2024 | 200 |
| NCT04639375SARS-CoV-2 · United States | 4 | UNKNOWN | E-MO Biology | Jun 12, 2021 | 300 |
| NCT04051736Vaccination · China | 4 | Completed | Sinopharm | Dec 28, 2018 | 360 |
| NCT03566940Healthy · Philippines | 2 | Completed | Johnson & Johnson | Aug 7, 2019 | 302 |
| NCT03526978Poliomyelitis · China | 3 | Completed | Sinovac Biotech | Oct 18, 2017 | 1,200 |
| NCT03092791Poliomyelitis · Panama | 2 | Terminated | Takeda | Apr 3, 2018 | 340 |
| NCT03032588Healthy · Belgium | 1 | Completed | Johnson & Johnson | May 18, 2018 | 32 |
| NCT01449812Tetanus · China | 3 | Completed | GlaxoSmithKline | Jan 16, 2012 | 831 |
| NCT01021293Poliomyelitis · China | 3 | Completed | GlaxoSmithKline | Jul 5, 2010 | 1,101 |
| NCT00937404Poliomyelitis · China | 1 | Completed | GlaxoSmithKline | Nov 13, 2009 | 25 |
| NCT00547248Streptococcal Infections · Philippines, Poland | 3 | Completed | GlaxoSmithKline | May 10, 2008 | 756 |
How it is read
Names in the registry
- “sIPV”, 6 entries
- “IPV”, 3 entries
- “Poliorix™”, 2 entries
- “Poliorix”, 2 entries
- “sIPV+bOPV”, 1 entry
Conditions, from the studies’ own filings
- Poliomyelitis, 9 studies
- Gastroenteritis, 2 studies
- Streptococcal Infections, 1 study
- Tetanus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.